Join Abivax for a Key Opinion Leader (KOL) Investor Webcast featuring renowned gastroenterologist Professor David T. Rubin, MD from The University of Chicago, who will provide expert insights into the evolving treatment landscape for ulcerative colitis (UC) and discuss expectations for Abivax’s ABTECT Phase 3 trial evaluating obefazimod in adults with moderately to severely active UC. He will also explore obefazimod’s potential to address critical unmet medical needs in UC treatment.

Obefazimod is an investigational oral therapy and is the first and only molecule that enhances the expression of miR-124, a natural regulator of the inflammatory response. Top-line 8-week induction trial results are expected in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, an NDA submission planned for H2 2026. The study is currently over 80% enrolled.

Following the presentation, attendees will have the opportunity to participate in a live Q&A session with Dr. Rubin and Abivax’s management team.